1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
250.58 USD   -0.25%
08/17AMGEN INC. : Ex-dividend day for
FA
08/16AMGEN : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act”
PU
08/16AMGEN CHRONICLES : Fresh Water and Fresher Ideas About Sustainability in Puerto Rico
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen to buy ChemoCentryx for $3.7 billion

08/04/2022 | 08:17am EDT
FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco

(Reuters) - Amgen Inc said on Thursday it would buy ChemoCentryx Inc for $3.7 billion to gain access to the company's anti-inflammation drug.

Amgen will pay $52 per share in cash, which represents a premium of nearly 116% to ChemoCentryx's closing price on Wednesday.

ChemoCentryx makes Tavneos, a drug approved to treat patients with a rare form of blood vessel inflammation. The therapy brought in sales of $5.4 million in the first full quarter since its launch.

The company has three drugs in early-stage trials to treat inflammatory diseases and is also developing a cancer drug.

(Reporting by Manas Mishra in Bengaluru; Editing by Aditya Soni)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. -0.25% 250.58 Delayed Quote.11.38%
CHEMOCENTRYX, INC. -0.16% 50.78 Delayed Quote.39.47%
VESSEL CO., LTD. -3.40% 7680 End-of-day quote.116.34%
All news about AMGEN INC.
08/17AMGEN INC. : Ex-dividend day for
FA
08/16AMGEN : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act&rd..
PU
08/16AMGEN CHRONICLES : Fresh Water and Fresher Ideas About Sustainability in Puerto Rico
PU
08/12AMGEN : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act&rd..
PU
08/12Biotech stocks pin bounce back hopes on M&A boost
RE
08/11Senate Finance Committee looks at Amgen taxes, widening drugmaker probe
RE
08/11Senate finance committee chairman wyden sends amgen letter inqui…
RE
08/09Atlantic Equities Adjusts Amgen's Price Target to $182 from $190, Keeps Underweight Rat..
MT
08/08AMGEN : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act&rd..
PU
08/08Amgen Presents New Tarlatamab Clinical Data At WCLC 2022
CI
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 162 M - -
Net income 2022 6 252 M - -
Net Debt 2022 27 064 M - -
P/E ratio 2022 21,3x
Yield 2022 3,10%
Capitalization 134 B 134 B -
EV / Sales 2022 6,16x
EV / Sales 2023 5,85x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 250,58 $
Average target price 250,10 $
Spread / Average Target -0,19%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.11.38%135 418
JOHNSON & JOHNSON-2.04%440 572
ELI LILLY AND COMPANY14.70%294 849
PFIZER, INC.-16.56%279 832
ROCHE HOLDING AG-16.74%273 886
ABBVIE INC.4.46%252 042